Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock

Key Points

• Insider sale: NovoCure insider Michal Nath Puri sold 1,100 shares on March 4 at an average price of $13.31 for $14,641, trimming his stake by 0.54% to 201,322 shares (approx. $2.68M).
• Quarterly results: NovoCure reported Q on Feb. 26 with EPS of -$0.22 beating the -$0.41 estimate and revenue of $174.35M (+8.2% YoY), but the company remains unprofitable with a -20.79% net margin and -39.11% ROE.
• Market and analyst view: NVCR traded at $14.23 (50/200-day MAs ≈ $12.7, 12‑month range $9.82–$21.55) with a $1.62B market cap; analyst coverage is mixed (3 Buy / 3 Hold / 1 Sell) with a consensus "Hold" and an average target of $26.93, while institutions own ~84.6% of the stock.

NovoCure Limited (NASDAQ:NVCR - Get Free Report) insider Michal Nath Puri sold 1,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $14,641.00. Following the completion of the transaction, the insider owned 201,322 shares in the company, valued at approximately $2,679,595.82. This trade represents a 0.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NovoCure Price Performance

Shares of NVCR traded up $0.81 during trading hours on Thursday, hitting $14.23. 2,315,394 shares of the stock were exchanged, compared to its average volume of 2,231,897. The stock's 50-day moving average price is $12.73 and its two-hundred day moving average price is $12.70. NovoCure Limited has a 12-month low of $9.82 and a 12-month high of $21.55. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.50 and a current ratio of 2.90. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -11.66 and a beta of 0.71.

NovoCure (NASDAQ:NVCR - Get Free Report) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The company had revenue of $174.35 million for the quarter, compared to analysts' expectations of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The firm's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.61) EPS. Research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HC Wainwright upped their price target on NovoCure from $47.00 to $49.00 and gave the company a "buy" rating in a research report on Thursday, February 26th. Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Wedbush reiterated a "neutral" rating and set a $18.00 price target on shares of NovoCure in a report on Thursday, January 15th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of NovoCure in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, NovoCure currently has a consensus rating of "Hold" and an average target price of $26.93.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NVCR. Empowered Funds LLC purchased a new position in NovoCure in the 4th quarter valued at approximately $33,000. SJS Investment Consulting Inc. acquired a new stake in shares of NovoCure in the third quarter valued at $41,000. Kestra Advisory Services LLC purchased a new position in NovoCure in the fourth quarter valued at $49,000. Larson Financial Group LLC grew its stake in NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider's stock worth $53,000 after purchasing an additional 3,562 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in NovoCure in the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 84.61% of the company's stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.